Josune Zubicaray

Josune Zubicaray

Auto-generated profile, based on publicly available information

Josune Zubicaray

Pediatric Hematology and Oncology Department and Foundation for Biomedical Research Pediatric University Hospital Niño Jesús, and Biomedical Network Research Center for Rare Diseases (CIBERER) Madrid Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2021 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
SFS. Fernández-Plaza
S. Fernández-Plaza
JPJ. González de Pablo
J. González de Pablo
EGE. Gálvez
E. Gálvez
JZJ. Zubicaray
J. Zubicaray
MGM. Guillén
M. Guillén
ESE. Sebastián
E. Sebastián

15 April 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PAPedro Aguilar-Garrido
Pedro Aguilar-Garrido
MVMaria Velasco-Estevez
Maria Velasco-Estevez
MNMiguel Ángel Navarro-Aguadero
Miguel Ángel Navarro-Aguadero
ÁOÁlvaro Otero-Sobrino
Álvaro Otero-Sobrino
MIMarta Ibáñez-Navarro
Marta Ibáñez-Navarro
MGMiguel Gallardo
Miguel Gallardo
The nucleolus is a membraneless organelle and an excellent stress sensor. Any changes in its architecture or composition lead to nucleolar stress, resulting in cell cycle arrest and interruption of ribosomal activity, critical factors in aging and cancer. In this study, we identified and described the pivotal role of the RNA-binding protein (RBP) HNRNPK in ribosome and nucleolar dynamics. We developed an in vitro model of endogenous HNRNPK overexpression and an in vivo mouse model of ubiquitous HNRNPK overexpression. These models showed disruptions in translation and caused alterations in the nucleolar structure, resulting in p53-dependent nucleolar stress, cell cycle arrest, senescence, and bone marrow failure phenotype, similar to what is observed in patients with ribosomopathies. Together, our findings identify HNRNPK as a master regulator of ribosome biogenesis (RiBi) and nucleolar homeostasis through p53, providing a new perspective on the orchestration of nucleolar integrity, ribosome function and cellular senescence.

1 February 2021 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
JZJosune Zubicaray
Josune Zubicaray
EGEva Galvez
Eva Galvez
ESElena Sebastian
Elena Sebastian
BMBlanca Molina
Blanca Molina
MGMarta González‐Vicent
Marta González‐Vicent
JSJulián Sevilla
Julián Sevilla

17 January 2023 in Vox Sanguinis
Verified
Journal Article
Closed access
SASatyam Arora
Satyam Arora
RGRuchika Goel
Ruchika Goel
AAArwa Z. Al‐Riyami
Arwa Z. Al‐Riyami
AAAbdul Hakim Al‐Rawas
Abdul Hakim Al‐Rawas
SHSaif Al Hosni
Saif Al Hosni
NDNancy Dunbar
Nancy Dunbar

27 April 2024 in Genes
Verified
Journal Article
Open access
PDF file
JIJune Iriondo
June Iriondo
AGAna Gómez
Ana Gómez
JZJosune Zubicaray
Josune Zubicaray
JMJorge García Martínez
Jorge García Martínez
LALorea Abad
Lorea Abad
JSJulián Sevilla
Julián Sevilla
Cytogenetic studies are essential in the diagnosis and follow up of patients with bone marrow failure syndromes (BMFSs), but obtaining good quality results is often challenging due to hypocellularity. Optical Genome Mapping (OGM), a novel technology capable of detecting most types chromosomal structural variants (SVs) at high resolution, is being increasingly used in many settings, including hematologic malignancies. Herein, we compared conventional cytogenetic techniques to OGM in 20 patients with diverse BMFSs. Twenty metaphases for the karyotype were only obtained in three subjects (15%), and no SVs were found in any of the samples. One patient with culture failure showed a gain in chromosome 1q by fluorescence in situ hybridization, which was confirmed by OGM. In contrast, OGM provided good quality results in all subjects, and SVs were detected in 14 of them (70%), mostly corresponding to cryptic submicroscopic alterations not observed by standard techniques. Therefore, OGM emerges as a powerful tool that provides complete and evaluable results in hypocellular BMFSs, reducing multiple tests into a single assay and overcoming some of the main limitations of conventional techniques. Furthermore, in addition to confirming the abnormalities detected by conventional techniques, OGM found new alterations beyond their detection limits.

4 June 2022 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
JIJune Iriondo
June Iriondo
JZJosune Zubicaray
Josune Zubicaray
ESElena Sebastián
Elena Sebastián
JPJesús González de Pablo
Jesús González de Pablo
MGMarta González‐Vicent
Marta González‐Vicent
JSJulián Sevilla
Julián Sevilla